Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Chinese Patent Office
Daiichi Sankyo
Queensland Health

Generated: November 18, 2017

DrugPatentWatch Database Preview

Details for Patent: 4,915,950

« Back to Dashboard

Summary for Patent: 4,915,950

Title: Printed transdermal drug delivery device
Abstract:A method for making transdermal drug delivery devices is provided which includes: laminating an adsorbent source layer to a pressure-sensitive, pharmaceutically acceptable contact adhesive; depositing a drug in liquid form on one face of the source layer; laminating an anchor adhesive layer to the opposing face of the source layer; and applying a drug-impermeable backing layer to the anchor adhesive, which backing layer then defines the upper surface of the device. The invention also encompasses transdermal drug delivery devices having a source layer in contact with and contained between anchor and contact adhesive layers, with a backing layer adjacent the anchor adhesive defining the upper surface of the device.
Inventor(s): Miranda; Jesus (Menlo Park, CA), Cleary; Gary W. (San Mateo, CA)
Assignee: Cygnus Research Corporation (Redwood City, CA)
Application Number:07/215,074
Patent Claim Types:
see list of patent claims
Use; Delivery; Device;

No matches for this query

International Patent Family for Patent: 4,915,950

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria127331► Subscribe
Australia4031289► Subscribe
Australia639892► Subscribe
Canada1336324► Subscribe
Germany68924157► Subscribe
Denmark191890► Subscribe
European Patent Office0400078► Subscribe
Spain2011416► Subscribe
Ireland73228► Subscribe
Ireland890453► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Fish and Richardson
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

Google Plus